R-PLEX Human Met (soluble) Overview The R-PLEX Human Met (soluble) includes a matched capture and detection antibody pair and calibrator for the quick and easy measurement of Met (soluble) in biological samples. R-PLEX products leverage MSD’s electrochemiluminescence technology for better sensitivity and a larger dynamic range than traditional ELISAs. R-PLEX matched antibody sets enable the development of singleplex and multiplex immunoassays. Individual assays may be developed using MSD avidin- or streptavidin-coated plates. Custom multiplex assays with any combination of R-PLEX analytes, as well as R-PLEX plus U-PLEX analytes can be developed on U-PLEX MULTI-SPOT plates. To learn more about the advantages of R-PLEX products
click here.
R-PLEX Human Met (soluble) Features - Measures human Met (soluble) in Serum, Plasma, Urine
- Dynamic range: 19 - 200,000 pg/mL
- Median LLOD: 19 pg/mL
- Can be used to develop individual analyte assays as well as multiplex panels
Typical Data Calibration curve for the R-PLEX Human Met (soluble) was assessed and representative data is presented below.
Figure 1. R-PLEX Human Met (soluble) Calibration Curve 
Met (soluble) Analyte
Description - Soluble Met (c-Met, AUTS9, HGFR, RCCP2, DFNB97, OSFD), also known as the hepatocyte growth factor receptor, is a proto-oncogene with tyrosine kinase activity. HGF activation of Met induces growth, proliferation, cell survival, motility, and angiogenesis. Due to the involvement of Met in many different types of cancers, there has been considerable research directed towards disruption of the HGF-Met signaling.
Application Area - Oncology, Liver and Kidney Disease
-
Recommended Components
-
Specifications
-
Kit Contents
-
References
-
Documentation
Why do I need other components
Catalog No.
Product Name
Size
R51BB-4
R50AA-4
R92TG-3
L45SA-1
|
Application(s)
|
|
Oncology & Cancer
,
Cardiovascular
|
|
Analyte(s)
|
|
Met
|
|
Species
|
|
Human
|
|
Capture Antibody
|
|
Mouse Monoclonal
|
|
Detection Antibody
|
|
Mouse Monoclonal
|
|
Dynamic Range
|
|
18.9-200,000 pg/mL
|
|
Sample Type
|
|
Serum, Plasma, Urine
|
|
Recombinant standards
|
|
Recombinant Expressed in mouse myeloma cell line, NS0
|
|
LLOD (Sensitivity)
|
|
18.9 pg/mL
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
Storage Statement(s)
|
|
Please refer to the product insert for the storage conditions of individual kit components.
|
|
Storage Condition
|
|
Multi-Component
|
|
Gene ID(s)
|
|
4233
|
|
UniProt ID(s)
|
|
P08581
|
|
Assay Diluent(s)
|
|
Diluent 2
|
|
Antibody Diluent(s)
|
|
Diluent 3
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
Human c-MET (soluble) Antibody Set (5 Plate Size)
|
2-8°C
|
1 ea
(5 plate size)
|
|
|
|
Human c-MET (soluble) Calibrator
|
≤-70°C
|
5 vial
(1 vial)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
Human c-MET (soluble) Antibody Set (5 Plate Size)
|
2-8°C
|
10 ea
(5 plate size)
|
|
|
|
Human c-MET (soluble) Calibrator
|
≤-70°C
|
50 vial
(1 vial)
|
|
|
|
Title
|
Journal
|
Year
|
|
Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.
|
|
|
|
Phase II study evaluating 2 dosing schedules of oral Foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.
|
|
|
|
S49076 is a novel kinase inhibitor of MET, AXL and FGFR with strong preclinical activity alone and in association with bevacizumab.
|
|
|
|
Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody Onartuzumab.
|
|
|
|
Targeted MET inhibition in castration-resistant prostate cancer: A randomized phase 2 study and biomarker analysis with Rilotumumab plus Mitoxantrone and Prednisone.
|
|
|
|
|
View All
|
|
Product Inserts
|
|
|
|
Product Highlights
|
|
|
|
SDS
|
|
|
|
Handouts
|
|
|
|
Datasheets
|
|
|
Order Details
Catalog No
Size
Price in USD
Qty
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters